Introduction

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 12, 2011, Pages 860-863

  Miao, Chao Yu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INSULIN; LEPTIN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; STEROID HORMONE;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; OBESITY; PHENOTYPE; THROMBOSIS; ANIMAL; EDITORIAL; MALE; METABOLISM; RAT;

ADIPOKINES; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MALE; OBESITY; RATS;

EID: 82355183529     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05598.x     Document Type: Article

References (30)

1. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since. 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-67.
2. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc. Res. 2009; 81: 370-80.
3. Kahn CR. Medicine. Can we nip obesity in its vascular bud? Science 2008; 322: 542-3.
4. Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br. J. Pharmacol. 2011; Epub 6 April 2011; doi:.
5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
6. Hirokawa J, Sakaue S, Furuya Y et al. Tumor necrosis factor-alpha regulates the gene expression of macrophage migration inhibitory factor through tyrosine kinase-dependent pathway in 3T3-L1 adipocytes. J. Biochem. 1998; 123: 733-9.
7. Hristova M, Aloe L, Ghenev PI, Fiore M, Chaldakov GN. Leptin and mast cells: A novel adipoimmune link. Turk. J. Med. Sci. 2001; 31: 581-3.
8. Nakao K, Yasoda A, Ebihara K, Hosoda K, Mukoyama M. Translational research of novel hormones: Lessons from animal models and rare human diseases for common human diseases. J. Mol. Med. 2009; 87: 1029-39.
9. Hou N, Luo JD. Leptin and cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 2011; 38: 905-13.
10. Hou N, Luo MS, Liu SM et al. Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor α pathway in cultured neonatal rat cardiomyocytes. Clin. Exp. Pharmacol. Physiol. 2010; 37: 1087-95.
11. Xu FP, Chen MS, Wang YZ et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004; 110: 1269-75.
12. Tao L, Gao E, Jiao X et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115: 1408-16.
13. Wang Y, Gao E, Tao L et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009; 119: 835-44.
14. Su H, Lau WB, Ma XL. Hypoadiponectinemia in Type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 2011; 38: 897-904.
15. Sacks HS, Fain JN. Human epicardial adipose tissue: A review. Am. Heart J. 2007; 153: 907-17.
16. Sacks HS, Fain JN. Human epicardial fat: What is new and what is missing? Clin. Exp. Pharmacol. Physiol. 2011; 38: 879-87.
17. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ. Res. 2007; 100: 1249-60.
18. Ye JP, Gimble JM. Regulation of stem cell differentiation in adipose tissue by chronic inflammation. Clin. Exp. Pharmacol. Physiol. 2011; 38: 872-78.
19. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes (Lond). 2009; 33: 54-66.
20. Moharir MD, Shroff M, Stephens D et al. Anticoagulants in pediatric cerebral sinovenous thrombosis: A safety and outcome study. Ann. Neurol. 2010; 67: 590-9.
21. Lip GY, Huber K, Andreotti F et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2010; 31: 1311-18.
22. Liebeskind DS. Imaging the future of stroke. II. Hemorrhage. Ann. Neurol. 2010; 68: 581-92.
23. Robaei D, Grieve SM, Nelson GC, Bhindi R, Figtree GA. Cocaine-induced epicardial coronary artery thrombosis resulting in extensive myocardial injury assessed by cardiac magnetic resonance imaging. Eur. Heart J. 2010; 31: 2446.
24. Schäfer K, Konstantinides S. Adipokines and thrombosis. Clin. Exp. Pharmacol. Physiol. 2011; 38: 864-71.
25. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. 2001; 108: 1533-40.
26. Wang P, Bai C, Xu QY et al. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2010; 37: 894-9.
27. Wang P, Xu TY, Guan YF et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann. Neurol. 2011; 69: 360-74.
28. Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio-cerebro-vascular disease. J. Cardiovasc. Pharmacol. 2011; Epub 22 January 2011; doi:.
29. Wang P, Yang FJ, Du H et al. Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass- and obesity-associated (FTO) downregulation during energy restriction. Mol. Med. 2011; 17: 523-32.
30. Li ZY, Wang P, Miao CY. Adipokines in inflammation, insulin resistance and cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 2011; 38: 888-96.